



Clinical trial results:

Single-arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome

Summary

EudraCT number	2013-000727-13
Trial protocol	BE
Global end of trial date	20 March 2017

Results information

Result version number	v1 (current)
This version publication date	02 March 2018
First version publication date	02 March 2018

Trial information

Trial identification

Sponsor protocol code	20130113
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02175277
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
Public contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
Scientific contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 March 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 March 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 study for subjects who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines.

All subjects provided written informed consent before undergoing any study-related procedures, including screening procedures.

The study protocol, amendments, and the informed consent form (ICF) were reviewed by the Institutional Review Boards (IRBs) and Independent Ethics Committees (IECs). No subjects were recruited into the study and no investigational product (IP) was shipped until the IRB/IEC gave written approval of the protocol and ICF and Amgen received copies of these approvals.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 June 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 9
Worldwide total number of subjects	9
EEA total number of subjects	9

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	1
From 65 to 84 years	8
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 5 centers in Belgium from 12 June 2014 (first subject enrolled) to 20 March 2017 (last subject completed study).

Pre-assignment

Screening details:

This study enrolled participants who completed the active treatment period of the phase 3 Study 20090160 (2013-000727-13).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Darbepoetin alfa
------------------	------------------

Arm description:

Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	Darbepoetin alfa
Investigational medicinal product code	
Other name	Aranesp®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 µg every two weeks (Q2W).

Number of subjects in period 1	Darbepoetin alfa
Started	9
Completed	8
Not completed	1
Protocol-specified criteria	1

Baseline characteristics

Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	9	9	
Age Categorical			
Units: Subjects			
Adults (18-64 years)	1	1	
From 65-84 years	8	8	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	71.3		
standard deviation	± 7.9	-	
Gender Categorical			
Units: Subjects			
Female	3	3	
Male	6	6	
Race			
Units: Subjects			
White	9	9	
Ethnicity			
Units: Subjects			
Hispanic/Latino	1	1	
Not Hispanic/Latino	8	8	

End points

End points reporting groups

Reporting group title	Darbepoetin alfa
Reporting group description:	
Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.	

Primary: Number of Participants with Treatment-emergent Adverse Events

End point title	Number of Participants with Treatment-emergent Adverse Events ^[1]
-----------------	--

End point description:

Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, where Grade 1 indicates a mild AE, Grade 2 indicates a moderate AE, Grade 3 indicates severe or medically significant but not immediately life-threatening and Grade 4 indicates life-threatening consequences; urgent intervention indicated.

A serious adverse event was defined as an adverse event that met at least one of the following serious criteria:

- fatal
- life threatening
- required in-patient hospitalization or prolongation of existing hospitalization
- resulted in persistent or significant disability/incapacity
- congenital anomaly/birth defect
- other medically important serious event

The investigator assessed whether each adverse events was related to darbepoetin alfa.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of darbepoetin alfa to 30 days after last dose; the maximum treatment duration was 73 weeks.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: All study results were descriptive, with no inferential testing.

End point values	Darbepoetin alfa			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: participants				
All adverse events	9			
Adverse events \geq grade 2	8			
Adverse events \geq grade 3	2			
Adverse events \geq grade 4	0			
Serious adverse events	3			
AEs leading to discontinuation of darbepoetin alfa	1			
Fatal adverse events	0			
Treatment-related adverse events	0			

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of darbepoetin alfa to 30 days after last dose; the maximum treatment duration was 73 weeks.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Darbepoetin alfa
-----------------------	------------------

Reporting group description:

Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.

Serious adverse events	Darbepoetin alfa		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 9 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Macular fibrosis			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Non-serious adverse events	Darbepoetin alfa		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)		
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	2		
Fatigue			
subjects affected / exposed	4 / 9 (44.44%)		
occurrences (all)	10		
Injection site haematoma			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 9 (33.33%)		
occurrences (all)	4		
Dysphonia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Dyspnoea			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea exertional</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Epistaxis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Oropharyngeal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rhinorrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>1</p> <p>4 / 9 (44.44%)</p> <p>8</p> <p>1 / 9 (11.11%)</p> <p>2</p> <p>3 / 9 (33.33%)</p> <p>4</p> <p>1 / 9 (11.11%)</p> <p>1</p>		
<p>Psychiatric disorders</p> <p>Depression</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>1</p>		
<p>Investigations</p> <p>Blood creatinine increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>1</p>		
<p>Injury, poisoning and procedural complications</p> <p>Contusion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Fall</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Upper limb fracture</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>2</p> <p>1 / 9 (11.11%)</p> <p>1</p> <p>1 / 9 (11.11%)</p> <p>1</p>		
<p>Cardiac disorders</p> <p>Palpitations</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>1</p>		

<p>Nervous system disorders</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>2 / 9 (22.22%)</p> <p>3</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>2 / 9 (22.22%)</p> <p>2</p> <p>Restless legs syndrome</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>1</p>			
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>2 / 9 (22.22%)</p> <p>2</p> <p>Neutropenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>1</p>			
<p>Eye disorders</p> <p>Chalazion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>1</p> <p>Visual acuity reduced</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>1</p>			
<p>Gastrointestinal disorders</p> <p>Abdominal discomfort</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>3 / 9 (33.33%)</p> <p>3</p> <p>Abdominal pain upper</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>3</p> <p>Abdominal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>1</p> <p>Aphthous ulcer</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 9 (11.11%)</p> <p>2</p>			

Diarrhoea			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Dry mouth			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Haematochezia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	2		
Inguinal hernia			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	2		
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Rash generalised			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Skin discomfort			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Urticaria			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2		
Renal and urinary disorders Nocturia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Bone pain subjects affected / exposed occurrences (all) Hypercreatinaemia subjects affected / exposed occurrences (all) Muscle spasms subjects affected / exposed occurrences (all) Musculoskeletal chest pain subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1 2 / 9 (22.22%) 2 1 / 9 (11.11%) 1 1 / 9 (11.11%) 2 1 / 9 (11.11%) 1 1 / 9 (11.11%) 1		
Infections and infestations Bronchitis subjects affected / exposed occurrences (all) Gingivitis subjects affected / exposed occurrences (all) Herpes simplex subjects affected / exposed occurrences (all) Influenza	1 / 9 (11.11%) 1 1 / 9 (11.11%) 1 1 / 9 (11.11%) 1		

subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	2 / 9 (22.22%)		
occurrences (all)	2		
Oral fungal infection			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 9 (11.11%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported